Publication

Since its launch in 2016, the Diagnostic Quality Assurance Pilot (“the pilot”) has aimed to create a process to compare the performance of molecular diagnostics tests for selection of targeted therapies in cancer treatment. The following memorandum provides an update on the pilot’s progress, milestones achieved, and next steps.